W
Wen-Juan Wang
Researcher at Centers for Disease Control and Prevention
Publications - 10
Citations - 1502
Wen-Juan Wang is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Vaccination & Ebola vaccine. The author has an hindex of 5, co-authored 8 publications receiving 1016 citations.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Feng Cai Zhu,Yu-Hua Li,Xu Hua Guan,Li Hua Hou,Wen-Juan Wang,Jing Xin Li,Shi Po Wu,Bu Sen Wang,Zhao Wang,Lei Wang,Si Yue Jia,Hu Dachuan Jiang,Ling Wang,Tao Jiang,Yi Hu,Jin Bo Gou,Sha Bei Xu,Jun-Jie Xu,Xue-Wen Wang,Wei Wang,Wei Chen +20 more
TL;DR: A dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain to assess the safety, tolerability, and immunogenicity.
Journal ArticleDOI
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
Fengcai Zhu,Alie H Wurie,Li-Hua Hou,Qi Liang,Yu-Hua Li,James B W Russell,Shipo Wu,Jingxin Li,Yuemei Hu,Guo Qiang,Wenbo Xu,Abdul R Wurie,Wen-Juan Wang,Zhe Zhang,Wen-Jiao Yin,Manal Ghazzawi,Xu Zhang,Lei Duan,Junzhi Wang,Wei Chen +19 more
TL;DR: The recombinant adenovirus type-5 vector-based Ebola vaccine was safe and highly immunogenic in healthy Sierra Leonean adults, and 8·0 × 1010 viral particles was the optimal dose.
Journal ArticleDOI
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Fengcai Zhu,Li-Hua Hou,Jingxin Li,Shipo Wu,Pei Liu,Gui-Rong Zhang,Yuemei Hu,Fan-Yue Meng,Junjie Xu,Rong Tang,Jie Zhang,Wen-Juan Wang,Lei Duan,Kai Chu,Qi Liang,Jialei Hu,Li Luo,Tao Zhu,Junzhi Wang,Wei Chen +19 more
TL;DR: The findings show that the high-dose vaccine is safe and robustly immunogenic and could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days.
Journal ArticleDOI
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Jingxin Li,Li-Hua Hou,Fan-Yue Meng,Shipo Wu,BS Yue-Mei Hu,BS Qi Liang,Kai Chu,BS Zhe Zhang,Jun-Jie Xu,Rong Tang,Wen-Juan Wang,ProfPhD Pei Liu,Jialei Hu,Li Luo,Rong Jiang,Fengcai Zhu,Wei Chen +16 more
TL;DR: The immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a homologous vector in healthy adults in China were analyzed.
Journal ArticleDOI
Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial.
Fengcai Zhu,Pengfei Jin,Tao Zhu,Wen-Juan Wang,Huayue Ye,Hongxing Pan,Li-Hua Hou,Jingxin Li,Xue Wang,Shi-Po Wu,Ying Wang,Jin-Bo Gou,Haitao Huang,Hongbin Wu,Xuewen Wang,Wei Chen +15 more
TL;DR: In this paper, the safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above were assessed.